NYSE: ADCT · Life Sciences · 4 alerts · CIK 1771910
Share price
$1.25Close, Nov 16
Market cap
$160M
Shares outstanding
127.67MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All ADC Therapeutics SA filings on SEC EDGAR ↗
ADC Therapeutics reported total revenue of $61.8 million for the nine months ended September 30, 2026, compared to $58.3 million in the prior year, driven primarily by growth in net product revenues. The company significantly reduced its operating expenses from $161.9 million to $126.8 million year-over-year, largely due to lower research and development costs and reduced restructuring charges.
ADC Therapeutics reported Q3 2026 net product revenue of $21 million and highlighted a strategic financial restructuring completed in October that extended its cash runway into 2029. The company also noted multiple upcoming data presentations for ZYNLONTA at the ASH 2026 annual meeting.
Term
Q3 2026
“During the third quarter, we made meaningful progress toward strengthening ADC Therapeutics' balance sheet and increasing strategic optionality while advancing clinical opportunities for ZYNLONTA®.”
Ameet Mallik, Chief Executive Officer of ADC Therapeutics
“The upcoming LOTIS-7 Phase 1b and marginal zone lymphoma IIT data at ASH highlights the potential for ZYNLONTA to play an important role in the treatment of r/r DLBCL and indolent lymphomas.”
Mohamed Zaki, M.D., Ph.D., Chief Medical Officer of ADC Therapeutics